Insulin Analogue Glargine Possibly Increases Cancer Risk

The risk of cancer possibly increases if patients with diabetes use the long-acting insulin analogue glargine instead of human insulin. Scientists analysed the data of almost 130,000 patients with diabetes in Germany who had been treated with either human insulin or the insulin analogues lispro, aspart or glargine between January 2001 and June 2005.
Full article >>